<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567943</url>
  </required_header>
  <id_info>
    <org_study_id>41552-G</org_study_id>
    <nct_id>NCT01567943</nct_id>
  </id_info>
  <brief_title>Contingency Management of Alcohol Abuse in the Severely Mentally ILL</brief_title>
  <acronym>CMETG</acronym>
  <official_title>Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the efficacy of a comprehensive 12-week contingency
      management intervention for treating alcohol dependence for persons with severe mental
      illness who are seen within the context of a community mental health center setting. The
      primary contingency will be submission of alcohol-free urines. Additional reinforcers will be
      provided for intensive outpatient addiction treatment attendance. Reinforcers will be
      vouchers or actual items useful for day-to-day living. Participants will be 120 adults
      diagnosed with alcohol dependance and severe mental illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The contingency management (CM) paradigm that will be used is the variable magnitude of
      reinforcement procedure. In order to encourage engagement in study procedures and reduce
      dropout in the randomized sample, all participants will undergo a 4-week pre-randomization
      induction period. During the induction period, participants will be reinforced for providing
      urine-tests three times a week. Those who demonstrate study participation and need for
      treatment during the induction period will be randomized to receive treatment as usual and
      either 1) 12 weeks of CM for alcohol abstinence (assessed by Ethyl glucuronide immunoassay
      urine-test) AND weekly reinforcement for intensive outpatient addiction treatment attendance;
      or 2) 12 weeks of reinforcement for providing urine-samples and continued study involvement.
      Randomization will be used to assign participants to treatment conditions.

      The primary outcome will be changes in alcohol use assessed by Ehyl glucuronide immunoassay
      urine-tests, breath-tests, as well as self- and clinician-reported alcohol use. The secondary
      outcome will be changes in intensive outpatient group attendance assessed by intensive
      outpatient clinician-report, as well as administrative data sources, and self-report. Other
      outcomes will include: urine-tests and self-reported illicit drug use, psychiatric symptoms,
      other outpatient treatment utilization, HIV-risk, and nicotine use. All outcomes will be
      assessed [for 4-weeks prior to study enrollment (self-report, clinician ratings etc)] and
      throughout the 4-week induction, 12-week intervention, and 3-month follow-up periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine</measure>
    <time_frame>Over 16 weeks of treatment (repeated measure)</time_frame>
    <description>Mean EtG value (in ng/mL). 150ng/mL or above = EtG-positive, 149ng/mL or below = EtG-negative. EtG = ethyl glucuronide, alcohol biomarker detectable in urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Intensive Outpatient Substance Abuse Treatment Attendance</measure>
    <time_frame>During 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Report Drug Use</measure>
    <time_frame>through 7 months of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Drug Use as Measured by Urinalysis</measure>
    <time_frame>through 7 months of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Community Outcomes</measure>
    <time_frame>entire study period, and three month prior and after study involvement</time_frame>
    <description>(jail bookings, ER visits, mental health and substance abuse service utilization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Symptomology</measure>
    <time_frame>throughout 7 months of study</time_frame>
    <description>Brief Symptom Inventory; Positive and Negative Symptom Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Alcohol Abuse</condition>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Contingency Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contingency Management plus treatment as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-contingent control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment as usual plus reinforcement for attendance</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Management</intervention_name>
    <description>Behavioral reinforcement for alcohol abstinence</description>
    <arm_group_label>Contingency Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Currently receiving psychiatric [AND intensive outpatient addiction treatment] at
             Community Psychiatric Clinic (CPC).

          2. Aged 18 to 65 years.

          3. Ability to understand written and spoken English language.

          4. DSM-IV diagnosis of alcohol dependence as assessed by the MINI psychiatric interview.

          5. Diagnosis of current serious mental illness: schizophrenia, schizoaffective disorders,
             bipolar disorder I or II, or recurring major depressive disorders as assessed by the
             MINI psychiatric interview.

          6. Alcohol use in the month prior to study entry: self-reported alcohol use of 5 days or
             more during the 30 days prior to study entry (5 drinking days/month is selected based
             on previous research reporting alcohol use in 18% of days assessed in a sample of
             psychiatric outpatients with co-occurring SUDs &amp; SMI).120

          7. A CPC treating clinician must affirm the potential participant is safe to participate
             in the study.

        Exclusion Criteria:

          1. A significant risk of dangerous alcohol withdrawal: a history of alcohol
             detoxification or seizure in the last 12 months AND participant or clinician concern
             that abstinence will induce dangerous alcohol withdrawal.

          2. DSM-IV diagnosis of current (last year) drug dependence as assessed by the MINI
             interview.

          3. Any medical/psychiatric condition, or severity of that condition, that in the opinion
             of the PI, would compromise safe study participation.

          4. Chart defined organic brain disorder or dementia.

          5. Inability to provide informed consent as measured by the University of California San
             Diego Brief Assessment of Capacity to Consent (UBACC), a tool designed to screen for
             ability to provide informed consent for research. If indicated by the UBACC screening
             process, the more comprehensive MacCAT-CR will be used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K Ries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael McDonell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <results_first_submitted>November 7, 2016</results_first_submitted>
  <results_first_submitted_qc>November 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2017</results_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Richard Ries</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>alcohol abuse</keyword>
  <keyword>drug abuse</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>contingency management</keyword>
  <keyword>psychosocial treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>123 participants were enrolled, but only 79 met criteria to be randomized. Criteria for randomization included: EtG-positive urine sample during 4-week pre-randomization phase of the study, and adequate attendance during the pre-randomization phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Contingency Management</title>
          <description>Contingency Management plus treatment as usual
Contingency Management: Behavioral reinforcement for alcohol abstinence</description>
        </group>
        <group group_id="P2">
          <title>Non-contingent Control Group</title>
          <description>Treatment as usual plus reinforcement for attendance</description>
        </group>
        <group group_id="P3">
          <title>Pre-randomization Drop-out</title>
          <description>These participants were enrolled/consented in the study but not randomized to the Contingency Management or Control conditions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Contingency Management</title>
          <description>Contingency Management plus treatment as usual
Contingency Management: Behavioral reinforcement for alcohol abstinence</description>
        </group>
        <group group_id="B2">
          <title>Non-contingent Control Group</title>
          <description>Treatment as usual plus reinforcement for attendance</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.55" spread="9.92"/>
                    <measurement group_id="B2" value="46.23" spread="10.55"/>
                    <measurement group_id="B3" value="45.38" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine</title>
        <description>Mean EtG value (in ng/mL). 150ng/mL or above = EtG-positive, 149ng/mL or below = EtG-negative. EtG = ethyl glucuronide, alcohol biomarker detectable in urine.</description>
        <time_frame>Over 16 weeks of treatment (repeated measure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Contingency Management</title>
            <description>Contingency Management plus treatment as usual
Contingency Management: Behavioral reinforcement for alcohol abstinence</description>
          </group>
          <group group_id="O2">
            <title>Non-contingent Control Group</title>
            <description>Treatment as usual plus reinforcement for attendance</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine</title>
          <description>Mean EtG value (in ng/mL). 150ng/mL or above = EtG-positive, 149ng/mL or below = EtG-negative. EtG = ethyl glucuronide, alcohol biomarker detectable in urine.</description>
          <units>EtG Value (nanograms per milileter)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.86" spread="39.57"/>
                    <measurement group_id="O2" value="734.79" spread="40.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Intensive Outpatient Substance Abuse Treatment Attendance</title>
        <time_frame>During 16 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Contingency Management</title>
            <description>Contingency Management plus treatment as usual
Contingency Management: Behavioral reinforcement for alcohol abstinence</description>
          </group>
          <group group_id="O2">
            <title>Non-contingent Control Group</title>
            <description>Treatment as usual plus reinforcement for attendance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intensive Outpatient Substance Abuse Treatment Attendance</title>
          <units>percentage of addiction tx attended</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="34"/>
                    <measurement group_id="O2" value="53" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self Report Drug Use</title>
        <time_frame>through 7 months of study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Drug Use as Measured by Urinalysis</title>
        <time_frame>through 7 months of study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Community Outcomes</title>
        <description>(jail bookings, ER visits, mental health and substance abuse service utilization)</description>
        <time_frame>entire study period, and three month prior and after study involvement</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychiatric Symptomology</title>
        <description>Brief Symptom Inventory; Positive and Negative Symptom Scale</description>
        <time_frame>throughout 7 months of study</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Contingency Management</title>
          <description>Contingency Management plus treatment as usual
Contingency Management: Behavioral reinforcement for alcohol abstinence</description>
        </group>
        <group group_id="E2">
          <title>Non-contingent Control Group</title>
          <description>Treatment as usual plus reinforcement for attendance</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael McDonell</name_or_title>
      <organization>Washington State University</organization>
      <phone>509 368-6967</phone>
      <email>mmcdonell@wsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

